Advanced Search
MyIDEAS: Login

Regolazione, innovazione e ciclo di vita dei prodotti - per una riforma del pricing al lancio e della governance della spesa nella farmaceutica pubblica

Contents:

Author Info

  • Chiara Bonassi

    (Autorità Garante della Concorrenza e del Mercato)

  • Fabio Pammolli

    ()
    (IMT Lucca Institute for Advanced Studies and CERM Foundation - Competitività, Regole, Mercati)

  • Massimo Riccaboni

    ()
    (IMT Lucca Institute for Advanced Studies and and Department of Managerial Economics, Strategy and Innovation, K.U. Leuven)

  • Nicola Carmine Salerno

    ()
    (EIOPA - European Insurance and Occupational Pensions Authority)

Abstract

All'indomani della pubblicazione della bozza di Finanziaria-2008, il Quaderno invita a riflettere su alcuni aspetti critici dell'articolo 5 in tema di spesa farmaceutica pubblica. L'analisi comparata delle dinamiche di settore/mercato induce a suggerire che: (a) le modalità di pricing al lancio distinguano chiaramente tra tipologie di prodotti (innovazioni significative, innovazioni incrementali, copie); (b) il pay-back segua regole meno discrezionali e distorsive di quelle proposte in Finanziaria; (c) maggior rilievo sia dato alla costruzione della cornice regolatoria (lato offerta e domanda) e al coordinamento Stato-Regioni nell'individuazione dell'agenda (non solo la responsabilizzazione finanziaria) e nella sua implementazione. Ci si augura che il Quaderno possa positivamente contribuire al dibattito lungo l'iter della Finanziaria.

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL: http://www.cermlab.it/wp-content/uploads/cerm/wp/wpcerm-2007-02.pdf
File Function: First version, 2007
Download Restriction: no

Bibliographic Info

Paper provided by Competitività Regole Mecati (CERM) in its series Working Papers with number 02-2007.

as in new window
Length: 50 pages
Date of creation: Oct 2007
Date of revision:
Handle: RePEc:ern:wpaper:02-2007

Contact details of provider:
Postal: Via Fiorentina, 1, 53100 Siena
Phone: +39 3488120691
Email:
Web page: http://www.cermlab.it/
More information through EDIRC

Related research

Keywords: spesa farmaceutica pubblica; pricing;

Find related papers by JEL classification:

References

References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
as in new window
  1. Patricia M. Danzon & Jonathan D. Ketcham, 2003. "Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand," NBER Working Papers 10007, National Bureau of Economic Research, Inc.
  2. Drummond, Michael & Jonsson, Bengt & Rutten, Frans, 1997. "The role of economic evaluation in the pricing and reimbursement of medicines," Health Policy, Elsevier, vol. 40(3), pages 199-215, June.
  3. Janos Kornai & Eric Maskin & Gerard Roland, 2002. "Understanding the Soft Budget Constraint," Economics Working Papers 0019, Institute for Advanced Study, School of Social Science.
  4. Danzon, Patricia M. & Chao, Li-Wei, 2000. "Cross-national price differences for pharmaceuticals: how large, and why?," Journal of Health Economics, Elsevier, vol. 19(2), pages 159-195, March.
  5. Fabio Pammolli & Nicola Carmine Salerno, 2007. "La distribuzione al dettaglio dei farmaci - tra regolazione efficiente e mercato," Working Papers 01-2007, Competitività Regole Mecati (CERM).
  6. Desmond Sheridan & Jim Attridge, 2006. "The Impact of Therapeutic Reference Pricing on Innovation in Cardiovascular Medicine," PharmacoEconomics, Springer, vol. 24(2), pages 35-54, December.
  7. Grabowski, Henry G & Vernon, John M, 1992. "Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act," Journal of Law and Economics, University of Chicago Press, vol. 35(2), pages 331-50, October.
  8. James W. Hughes & Michael J. Moore & Edward A. Snyder, 2002. ""Napsterizing" Pharmaceuticals: Access, Innovation, and Consumer Welfare," NBER Working Papers 9229, National Bureau of Economic Research, Inc.
  9. Patricia M. Danzon & Mark V. Pauly, 2002. "Health Insurance and the Growth in Pharmaceutical Expenditures," Journal of Law and Economics, University of Chicago Press, vol. 45(S2), pages 587-613.
Full references (including those not matched with items on IDEAS)

Citations

Lists

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

Statistics

Access and download statistics

Corrections

When requesting a correction, please mention this item's handle: RePEc:ern:wpaper:02-2007. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ().

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.